100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
TEST BANK-Marilyne M. Lange, Cornelis J. H. van de Velde (auth.), Vincenzo Valentini, Hans-Joachim Schmoll, Cornelis J. H. van de Velde (eds.) - Multidisciplinary Management of Rectal Cancer_ Question $9.49
Add to cart

Exam (elaborations)

TEST BANK-Marilyne M. Lange, Cornelis J. H. van de Velde (auth.), Vincenzo Valentini, Hans-Joachim Schmoll, Cornelis J. H. van de Velde (eds.) - Multidisciplinary Management of Rectal Cancer_ Question

 0 purchase
  • Course
  • Institution

Marilyne M. Lange, Cornelis J. H. van de Velde (auth.), Vincenzo Valentini, Hans-Joachim Schmoll, Cornelis J. H. van de Velde (eds.) - Multidisciplinary Management of Rectal Cancer_ Question & Answers

Preview 4 out of 343  pages

  • October 20, 2023
  • 343
  • 2023/2024
  • Exam (elaborations)
  • Questions & answers
avatar-seller
Multidisciplinary Management
of Rectal Cancer

,Contents




Part I Introduction

1 What Do We Consider Cancer of the Rectum?. . . . . . . . . . . . . 3
Marilyne M. Lange and Cornelis J.H. van de Velde
2 What Is the Ongoing Recommendation in the
Management of Rectal Cancer? . . . . . . . . . . . . . . . . . . . . . . . . . 9
Vincenzo Valentini, Hans-Joachim Schmoll,
and Cornelis J.H. van de Velde

Part II Q&As on Risk Factor Identification

3 What Prognostic Clinical Factors Must Be Considered
Before Treatment? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Claus Rödel
4 What Are the Relevant Imaging Factors to Optimize
Treatment Decisions?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Manish Chand and Gina Brown
5 What Biochemical and Molecular Biological Factors
Have Greater Relevance to Treatment Decisions? . . . . . . . . . . 41
Guido Lammering and Jeroen Buijsen
6 Do Different Populations of Rectal Cancer Exist? . . . . . . . . . . 49
Vincenzo Valentini, Francesco Cellini, Maria Cristina Barba,
and Ruud van Stiphout

Part III Q&As on Imaging

7 How Can We Identify Tumour Penetration?. . . . . . . . . . . . . . . 59
Manish Chand and Gina Brown
8 How Can We Identify Mesorectal Fascia Involvement?. . . . . . 67
Regina G.H. Beets-Tan
9 How Can We Identify Nodal Involvement? . . . . . . . . . . . . . . . . 73
Regina G.H. Beets-Tan
10 How Can We Identify Pathologic Complete Responders
After Radiochemotherapy?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
Brunella Barbaro and Lucia Leccisotti

ix

,x Contents


11 How Can We Identify Local Relapse? . . . . . . . . . . . . . . . . . . . . 95
Doenja M.J. Lambregts and Regina G.H. Beets-Tan

Part IV Q&As on Radiotherapy

12 When Should Preoperative Short-Course Radiotherapy
or Long-Course Chemoradiotherapy Be Performed? . . . . . . . 105
David Sebag-Montefiore and Robert Glynne-Jones
13 Should We Tailor the Delineation of Pelvic Structures
According to Tumor Presentation? . . . . . . . . . . . . . . . . . . . . . . 117
Maria Antonietta Gambacorta and Vincenzo Valentini
14 What Is the Role of IMRT and IGRT in Rectal Cancer?. . . . . 129
Jasper Nijkamp, Karin Haustermans, and Corrie A.M. Marijnen
15 What Are the Dose-Volume Constraints to Reduce
Late Toxicity? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Krzysztof Bujko
16 What Is the Contribution of Intraoperative Radiotherapy
(IORT) in Tailoring Local Therapy in Primary or Recurrent
Rectal Cancer? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
Felipe A. Calvo
17 What Is the Contribution of Brachytherapy in Tailoring
Local Therapy? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Jean-Pierre Gérard, Te Vuong, Jean-Michel Hannoun-Lévi,
and Arthur Sun Myint

Part V Q&As on Chemotherapy

18 Should Oxaliplatin Be Added to Preoperative
Chemoradiation? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
Carlo Aschele
19 Should Biologic Targeted Agents Be Combined
with Preoperative Chemoradiation in Rectal Cancer? . . . . . . 181
Pieter-Jan Cuyle and Eric Van Cutsem
20 Should Upfront Chemotherapy Precede Preoperative
Chemoradiation and Surgery? . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Carlos Fernandez-Martos and Xabier Garcia de Albeniz
21 How to Achieve Long-Term Survival in Patients
with Metastatic Rectal Cancer? . . . . . . . . . . . . . . . . . . . . . . . . . 205
Alexander Stein and Hans-Joachim Schmoll
22 Will Adjuvant Chemotherapy Improve Outcome
After Preoperative Chemoradiation?. . . . . . . . . . . . . . . . . . . . . 217
Bengt Glimelius and Peter Nygren

, Contents xi


Part VI Q&As on Surgery

23 How to Evaluate the Quality of Surgery? Suggestions
for Critical Reading of Surgical and Pathological Reports . . . 229
Lars Påhlman
24 How Is Nerve-Sparing Surgery Well Performed?. . . . . . . . . . . 233
Zoran Krivokapic and Ivan Dimitrijevic
25 Is Laparoscopic Rectal Surgery the Gold Standard? . . . . . . . . 249
David Jayne and Laeeq Khan
26 Is a Diverting Stoma Always Necessary for a Low
Anterior Resection of a Rectal Cancer?. . . . . . . . . . . . . . . . . . . 257
Geerard L. Beets
27 Will Extralevator Abdominoperineal Excision Become
the New Gold Standard? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261
Ingrid Martijnse, Nicholas West, Phil Quirke, Richard Heald,
Cornelius J.H. van de Velde, and Harm Rutten
28 Which Patients Do Benefit from Extended Resections
in Case of Locally Advanced Rectal Cancer? . . . . . . . . . . . . . . 275
Ralph L. Dudink, Miranda Kusters, and Harm Rutten
29 Can Standard Surgical Procedure Reliably Be Avoided
in Major Responders After Radio(chemo)therapy?. . . . . . . . . 291
Claudio Coco and Gianluca Rizzo

Part VII Q&As on Pathology

30 What Is the Correct Procedure for Handling
the Surgical Specimen? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
Nigel Scott
31 What Is the Prognostic Value of (y)pT and (y)pN?. . . . . . . . . . 319
Nadine Ectors
32 What Is the Prognostic Value of CRM Involvement?. . . . . . . . 327
Iris D. Nagtegaal
33 What Is the Prognostic Value of TRG? . . . . . . . . . . . . . . . . . . . 333
Fabio M. Vecchio

Part VIII Q&As on Multidisciplinary Team Management

34 What Are the Recommendations to Ensure a Successful
Multidisciplinary Team in Rectal Cancer? . . . . . . . . . . . . . . . . 341
Sujay Shah, Pawan Mathur, and Robert Glynne-Jones

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller japplications987. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $9.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

65352 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling

Recently viewed by you


$9.49
  • (0)
Add to cart
Added